Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Chronic kidney disease
•
Nephrology
Do you prefer prescribing lubiprostone over conventional stool softeners in patients with CKD and constipation?
Sumida K, et al., PMID 40591438
Related Questions
How do you choose between initiating long-term therapy with mTOR inhibitors versus opting for interventional treatments such as embolization or surgery in a patient with tuberous sclerosis, experiencing flank pain, and with renal angiomyolipomas larger than 4 cm?
Do you have a preference between an ACEi and ARB when initiating therapy for a patient with diabetic kidney disease, albuminuria, and hypertension?
Do you plan to initiate combination therapy with an SGLT-2 inhibitor and finerenone, instead of an SGLT-2 inhibitor alone, when treating patients with proteinuric chronic kidney disease and type 2 diabetes in light of the CONFIDENCE trial findings?
Would you avoid SGLT2 inhibitors in patients with nephrostomy tubes?
What are your top takeaways from ASN 2024?
How do you tailor protein intake recommendations for older patients with stages 3-5 non-dialysis dependent CKD, considering the unique metabolic and physiologic factors that influence protein metabolism in this population?
Under what circumstances would you obtain MR imaging of the kidneys in a patient with ADPKD who was recently diagnosed following CT imaging?
Do you recommend delaying spot urine protein quantification testing until after nephrostomy tube removal in a patient with obstructive uropathy?
How do you approach the management of ADPKD in pregnancy, considering the need to stop tolvaptan therapy?
If a patient who has tolerated allopurinol for a prolonged period of time is subsequently found to be positive for the HLA-B*58:01 gene, how would you manage urate-lowering therapy thereafter?
